After tough year, Moderna CEO confronts challenges for RSV, COVID businesses in shareholder letter Inventory write-downs and manufacturing charges are nothing new for Moderna, which has struggled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback